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Abstract
Parkinson’s disease is characterized by progressive cell death in the substantia nigra pars compacta, which leads to
dopamine depletion in the striatum and indirectly to cortical dysfunction. Increased glutamatergic transmission in
the basal ganglia is implicated in the pathophysiology of Parkinson’s disease and glutamate receptor mediated
excitotoxicity has been suggested to be one of the possible causes of the neuronal degeneration. In the present
study, the effects of serotonin, gamma-aminobutyric acid and bone marrow cells infused intranigrally to substantia
nigra individually and in combination on unilateral 6-hydroxydopamine induced Parkinson’s rat model was
analyzed. Scatchard analysis of total glutamate and NMDA receptor binding parameters showed a significant
increase in Bmax (P < 0.001) in the cerebral cortex of 6-hydroxydopamine infused rat compared to control. Real
Time PCR amplification of NMDA2B, mGluR5, bax, and ubiquitin carboxy-terminal hydrolase were up regulated in
cerebral cortex of 6-hydroxydopamine infused rats compared to control. Gene expression studies of GLAST,
ά-Synuclien and Cyclic AMP response element-binding protein showed a significant (P < 0.001) down regulation in
6-OHDA infused rats compared to control. Behavioural studies were carried out to confirm the biochemical and
molecular studies. Serotonin and GABA along with bone marrow cells in combination showed reversal of
glutamate receptors and behaviour abnormality shown in the Parkinson’s rat model. The therapeutic significance in
Parkinson’s disease is of prominence.
Background
Parkinson’s disease (PD), one of the most prevalent neu-
rodegenerative disorders among the elderly population, is
charecterised by dopamine neurons degeneration in the
substantia nigra pars compacta. Which makes an impact
on ascending adrenergic and serotonergic networks, fron-
tocortical cholinergic projections, and a diversity of neu-
ronal circuits located not only in the brain (from the
cortex to the medulla), but even in the spinal cord and
sympathetic nervous system [1,2]. Recent studies have
shown abnormal mitochondrial content and function,
also an increased oxidative stress and oxidative responses
in the cerebral cortex in PD [3]. According to the
classical model of basal ganglia organization, the usual
facilitating effect of thalamic projections to the cerebral
cortex is reduced in PD [4]. The motor dysfunction of
PD is generally accompanied by depressed affect and cog-
nitive impairment, comprising the triad of deficits that
most profoundly interfere with patient quality of life [5].
Antagonising excitotoxicity has been considered to have
therapeutic potential for the treatment of PD. Glutamate
neurotransmission plays an integral role in basal ganglia
functioning especially in the striatum, where the balance
of glutamate and dopamine is critical but also in the sub-
stantia nigra which receives glutamatergic input from the
subthalamic nucleus and cortex [6]. At physiological con-
centrations, glutamate mediates learning and memory
processes [7]. However, at high concentrations, glutamate
acts as a neurotoxin and promotes neuronal cell injury
and death in PD [8].
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mising approach for the treatment of progressive neuro-
degenerative diseases. Autologous bone marrow cells
(BMC) can be used as a source of progenitor cells for
the central nervous system. It circumvents both ethical
and immunological constraints related with stem cell
therapy. Neurotransmitter’s combination as therapeutic
agents for cell proliferation and differentiation is a novel
approach. In rats, 5-HT neurons in the brainstem raphe
are among the first neurons to differentiate in the brain
and play a key role in regulating neurogenesis [9]. Lau-
der and Krebs [10] reported that parachlorophenylala-
nine (PCPA), a 5-HT synthesis inhibitor, retarded
neuronal maturation, while mild stress, a releaser of
hormones, accelerated neuronal differentiation. These
workers defined differentiation as the cessation of cell
division measured by incorporation of
3H-thymidine.
Since then, many other workers have shown a role for
serotonin in neuronal differentiation [11]. GABA, the
main inhibitory neurotransmitter in the mature CNS,
was recently implicated in playing a complex role during
neurogenesis [12,13]. Through embryonic development,
GABA was demonstrated as acting as a chemo-
attractant and being involved in the regulation of pro-
genitor cell proliferation. For example, GABA induces
migration and motility of acutely dissociated embryonic
cortical neurons [12,14]. GABA acts as a trophic factor
not solely during prenatal neurogenesis but also in the
postnatal period in injured tissue. The effect of GABA
involves stimulation of cell proliferation and Nerve
growth factor secretion [15]. We have previously shown
that Serotonin (5HT) and Gamma aminobutyric acid
(GABA) acting through specific receptor subtypes 5HT2
[16] and GABAA [17] respectively, control cell prolifera-
tion and act as comitogens. Our present study demon-
strates the structural and molecular changes of
6-OHDA infused unilateral Parkinson’sm o d e lu s i n g
5-HT, GABA and BMC individually and in combination.
Materials and methods
Animals
Experiments were carried out on adult male Wistar rats of
250-300 g body weight purchased from Kerala Agricultural
University, Mannuthy, were used for all experiments. They
were housed in separate cages under 12 hrs light and
12 hrs dark periods and were maintained on standard
food pellets and water ad libitum. All animal care and
procedures were taken in accordance with the Institu-
tional, National Institute of Health guidelines and
CPCSEA guidelines.
Chemicals used and their sources
Biochemicals, Tri-reagent kit, primary and secondary
antibodies used in the present study were purchased
from Sigma Chemical Co., St. Louis, USA. All other
reagents were of analytical grade purchased locally.
L-[G-
3H]Glutamic acid (Sp. Activity 49.0 Ci/mmol) was
purchased from Amersham Life Science, UK. (+)-[3-
3H]
MK-801 (Sp. Activity 27.5 Ci/mmol) was purchased
from Perkin Elmer, Boston, MA, USA. ABI PRISM High
Capacity cDNA Archive kit, Primers and Taqman
probes for Real-Time PCR were purchased from Applied
Biosystems, Foster City, CA, USA.
Experimental design
The experimental rats were divided into the following
groups i) Control ii) 6-OHDA infused (6-OHDA) iii)
6-OHDA infused supplemented with Serotonin (6-OHDA
+ 5-HT) and iv) 6-OHDA infused supplemented with
GABA (6-OHDA + GABA) v) 6-OHDA infused supple-
mented with Bone marrow cells (isolated from rats on
femur) (6-OHDA + BMC) vi) 6-OHDA infused supple-
mented with 5-HT and BMC (6-OHDA+5-HT+BMC) vii)
6-OHDA infused supplemented with GABA and BMC
(6-OHDA+ GABA+BMC) viii) 6-OHDA infused supple-
mented with 5-HT, GABA and BMC (6-OHDA+5-HT
+GABA+BMC). Each group consisted of 6-8 animals.
Rats were anesthetized with Chloryl Hydrate (450 mg/kg
body weight. i.p.). The animal was placed in the flat skull
position on a cotton bed on a stereotaxic frame (Bench-
mark™, USA) with incisor bar fixed at 3.5 mm below the
interaural line. 6-OHDA (8 μgi n1μl in 0.2% ascorbic
acid) was infused into the right Substantia nigra Pars com-
pacta (SNpc) at a flow rate of 0.2 μl/min. After stopping
the infusion of the toxin, the probe was kept in the same
position for a further 5 min for complete diffusion of the
drug and then slowly retracted. All the groups except
Control group were infused with 6-OHDA and in control
animals, 1 μl of the vehicle (0.2% ascorbic acid) was
infused into the right SNpc.
Rotational behavior
Amphetamine-induced rotational behavior was assessed
as described earlier [18]. Rats were tested with ampheta-
mine on the 14
th day after intranigral injection of
6-OHDA and with apomorphine on the 16
th day. Ani-
mals that had completed a 360
◦ circle towards the intact
(contralateral) and the lesioned (ipsilateral) sides were
counted for 60 min continuously and recorded sepa-
rately (animals that showed no significant contralateral
rotations were excluded from the study).
Treatment
On the 18
th day and Stereotaxic single dose of 1 μlo f
5-HT (10 μg/μl), GABA(10 μg/μl) and 10 μl of Bone mar-
row cell (BMC) (10
6 Cells/ml) suspension individually
and in combination (combinational treatment) was
infused into the right SNpc at a flow rate of 0.2 μl/min
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th day and the apo-
morphine-induced rotations were recorded for every
10 min duration for a period of 70 min (Figure 1). All the
control and experimental rats were sacrificed by decapi-
tation. The cerebral cortex was dissected out quickly over
ice [19] and the tissues were stored at -80°C for various
experiments.
Quantification Dopamine in the cerebral cortex
The monoamines were assayed according to the modified
procedure of Paulose et al., [20]. The cerebral cortex of
experimental gropes of rats was homogenised in 0.4N
perchloric acid. The homogenate was then centrifuged at
5000 × g for 10 minutes at 4°C in a Sigma 3K30 refriger-
ated centrifuge and the clear supernatant was filtered
through 0.22 μm HPLC grade filters and used for HPLC
analysis.
Dopamine (DA) contents was determined in high per-
formance liquid chromatography (HPLC) with electroche-
mical detector (ECD) (Waters, USA) fitted with CLC-ODS
reverse phase column of 5 μm particle size. The mobile
phase consisted of 50 mM sodium phosphate dibasic,
0.03M citric acid, 0.1 mM EDTA, 0.6 mM sodium octyl
sulfonate, 15% methanol. The pH was adjusted to 3.25
with orthophosphoric acid, filtered through 0.22 μm filter
(Millipore) and degassed. A Waters (model 515, Milford,
USA) pump was used to deliver the solvent at a rate of
1 ml/minute. The neurotransmitters and their metabolites
were identified by amperometric detection using an
electrochemical detector (Waters, model 2465) with a
reduction potential of +0.80 V. Twenty microlitre aliquots
of the acidified supernatant were injected into the system
for detection. The peaks were identified by relative reten-
tion times compared with external standards and quantita-
tively estimated using an integrator (Empower software)
interfaced with the detector.
Glutamate content analysis in the cerebral cortex
Glutamate contents in the cerebral cortex of experimen-
tal groups were quantified by displacement method
using modified procedure of Enna and Snyder [21].
Tissue was homogenized in 20 volumes of 0.32 M
sucrose, 10 mM Tris/HCl and 1 mM MgCl2 buffer,
pH 7.4, with a polytron homogenizer. The homogenate
was centrifuged twice at 27,000 × g for 15 minutes. The
supernatant were pooled and used for the assay. The
incubation mixture for glutamate quantification con-
tained 1 nM [
3H] glutamate with and without glutamate
at a concentration range of 10
-9 Mt o1 0
-4 M.
Glutamate Receptor Binding Studies Using [
3H]Glutamate
Membranes were prepared according to the modified
method of Timothy et al., [22]. Membranes were incu-
bated in 0.25 ml reaction mixture containing 25 mM
T r i s - H C l ,p H7 . 4 ,5m MM g C l 2 and 20 nM to 350 nM
of [
3H]Glutamate containing 0.2 mg to 0.3 mg protein
concentrations. Nonspecific binding was determined by
adding 350 μM nonradioactive glutamate to the reaction
mixture in a parallel assay.
NMDA Receptor Binding Studies Using [
3H] MK-801
The membrane fractions were prepared by a modification
of the method described by Hoffman et al., [23]. The [
3H]
MK-801 binding saturation assay was performed in a
concentration range of 0.25 to 50 nM at 23°C in an assay
medium containing 10 mM HEPES, pH 7.0, 200 - 250 μg
of protein, 100 μM glycine and 100 μM glutamate. Speci-
fic [
3H] MK-801 binding was obtained by subtracting
nonspecific binding in the presence of 100 μM unlabeled
MK-801 from the total binding.
Protein Determination
Protein was measured [24] using bovine serum albumin
as standard. The intensity of the purple blue colour
formed was proportional to the amount of protein
which was read in a spectrophotometer at 660 nm.
Analysis of the Receptor-Binding Data
Linear Regression Analysis for Scatchard Plots
T h ed a t aw e r ea n a l y s e d[ 2 5 ] .T h es p e c i f i cb i n d i n gw a s
determined by subtracting non-specific binding from the
total. The binding parameters, maximal binding (Bmax)
and equilibrium dissociation constant (Kd), were derived
a
b,e
c,d
Figure 1 Apomorphine induced rotational behaviour in
experimental rats. Adult male Wistar rats were intranigrally infused
with 6-OHDA (8 μgi n1μl). Bone marrow cell and neurotransmitters
were infused individually and in combination in denervated striatum
on the 18
th day. Animals were injected with apomorphine (1 mg/kg;
s.c.) on the 30
th day and the apomorphine-induced rotations were
recorded for every 10 min duration for a period of 70 min. Values are
Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8
rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control.
dp < 0.001,
e p < 0.01 when compared to 6-OHDA group.
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binding of the radioligand on the X-axis and bound/free
on the Y-axis. The maximal binding is a measure of the
total number of receptors present in the tissue and
the equilibrium dissociation constant is the measure of
the affinity of the receptors for the radioligand. The Kd
is inversely related to receptor affinity.
Quantification of IP3
The cerebral cortex was homogenised in a polytron
homogeniser in 50 mM Tris-HCl buffer, pH.7.4, con-
taining 1 mM EDTA to obtain a 15% homogenate. The
homogenate was then centrifuged at 40,000 × g for
15 min. and the supernatant was transferred to fresh
tubes for IP3 assay using [
3H]IP3 Biotrak Assay System
kit. The unknown concentrations were determined from
the standard curve using appropriate dilutions and cal-
culated for picomoles/g wt. of the tissue.
A standard curve was plotted with %B/Bo on the
Y-axis and IP3 concentration (pmoles/tube) on the
X-axis of a semi-log graph paper. %B/Bo was calculated as:
()
()
Standard or sample cpm NSB cpm
B cpm NSB cpm
−
−
×
0
100
NSB- non specific binding and B0 - zero binding. IP3
concentrations in the samples were determined by inter-
polation from the plotted standard curve.
cAMP content in the cerebral cortex of control and
experimental rats
The cerebral cortex was homogenised in a polytron
homogeniser with cold 50 mM Tris-HCl buffer, pH 7.4,
containing 1 mM EDTA to obtain a 15% homogenate.
The homogenate was then centrifuged at 40,000 × g for
15 min and the supernatant was transferred to fresh
tubes for cAMP assay using [
3H]cAMP Biotrak Assay
System kit. The unknown concentrations were deter-
mined from the standard curve using appropriate dilu-
tions and calculated for picomoles/g wt. of the tissue.
Co/Cx was plotted on the Y-axis against picomoles of
inactive cAMP on the X- axis of a linear graph paper,
where Co is the counts per minute bound in the absence
of unlabelled cAMP and Cx was the counts per minute
bound in the presence of standard or unknown unla-
belled cAMP. From the Co/Cx value for the sample, the
number of picomoles of unknown cAMP was calculated.
Analysis of gene expression by real-time polymerase chain
reaction
RNA was isolated using Tri reagent. Total cDNA synthesis
was performed using ABI PRISM cDNA Archive kit. Real-
Time PCR assays were performed in 96-well plates in ABI
7300 Real-Time PCR instrument (Applied Biosystems).
PCR analyses were conducted with gene-specific primers
and fluorescently labelled Taqman probe of NMDA2B,
mGluR5, GLAST, bax, ά-Synuclien, ubiquitin carboxy-
terminal hydrolase and Cyclic AMP response element-
binding protein (CREB) (designed by Applied Biosystems).
Endogenous control, b-actin, was labeled with a report
dye, VIC.
NMDA2B and mGluR5 Receptor Expression using Confocal
Microscope
The rat was transcardially perfused with PBS, pH- 7.4, fol-
lowed by 4% paraformaldehyde in PBS [26]. 10 μmb r a i n
sections were cut using Cryostat (Leica, CM1510 S).
Brain slices were incubated overnight at 4°C with rat
primary antibody for NMDA2B and mGluR5. After over-
night incubation brain slices were incubated with the
secondary antibody of FITC. The sections were observed
and photographed using confocal imaging system (Leica
SP 5).
Statistical Analysis
Statistical evaluations were done with analysis of var-
iance (ANOVA), using GraphPad Instat (version 2.04a,
San Diego, USA). Student Newman-Keuls test was used
to compare different groups after ANOVA. Linear
regression Scatchard plots were made using SIGMA
PLOT (Ver 2.03). Relative Quantification Software was
used for analyzing Real-Time PCR results.
Results
Dopamine content in the cerebral cortex
6-OHDA infusion in to the SNpc resulted in a signifi-
cant (p < 0.001) decrease in dopamine content in the
cerebral cortex of PD rats. Dopamine production was
lower in the rats treated with 5-HT, GABA, BMC indi-
vidually. Combinational treatment significantly reversed
the dopamine content to near control level (Table 1).
Glutamate, IP3 and cAMP content in the cerebral cortex
Glutamate, IP3 and cAMP content showed a significant
increase in cerebral cortex of 6-OHDA rats compared to
control. Individual treatment with BMC, 5-HT and
GABA didn’t alter the changes. Combinational treat-
ment significantly reversed the content values to near
control level (Figure 2, 3 and 4).
Total glutamate receptor analysis
Scatchard analysis of [
3H]glutamate against glutamate in
cerebral cortex of 6-OHDA group of rats showed a sig-
nificant (p < 0.001) increase in Bmax compared to con-
trol rats. 6-OHDA+BMC group treated rats didn’t
reverse these changes. Combinational treatment signifi-
cantly (p < 0.001) reversed these changes to near con-
trol. There was no significant change in Kd in all
experimental groups (Table 2).
NMDA receptor analysis
Scatchard analysis of [
3H]MK-801 against MK-801 in
cerebral cortex of 6-OHDA group of rats showed a
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control rats. Individual treatment group rats didn’t
reverse these changes. Combinational treatment signifi-
cantly (p < 0.001) reversed these changes to near control.
There was no significant change in Kd in all experimental
groups indicating that there is no change in the affinity
of the receptors. This increased Bmax reflected an
increased number of NMDA receptors in the experimen-
tal groups (Table 3).
Real time PCR analysis of NMDA2B, mGluR5, GLAST, bax,
ά-Synuclien, ubiquitin carboxy-terminal hydrolase and
CREB
Gene expression studies of NMDA2B, mGluR5, bax and
ubiquitin carboxy-terminal hydrolase showed a signifi-
cant (P < 0.001) up regulation in 6-OHDA infused rats
Table 1 Dopamine Content (pmol/mg protein) in the
Cerebral cortex of experimental rats
Animal status Dopamine Content
(pmol/mg protein)
Control 57.05 ± 2.90
6-OHDA 3.57 ± 1.34
a
6-OHDA +5HT 14.21 ± 1.51
b,f
6-OHDA +GABA 13.38 ± 1.64
b,f
6-OHDA +BMC 5.24 ± 2.25
a
6-OHDA +5HT + BMC 37.82 ± 3.47
c,e
6-OHDA + GABA + BMC 39.63 ± 3.82
c,e
6-OHDA +5HT + GABA+ BMC 50.41 ± 3.02
c,d
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control.
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused
treated with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA,
6-OHDA +BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC-
6-OHDA infused treated with Serotonin and BMC, 6-OHDA + GABA +BMC-
6-OHDA infused treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC-
6-OHDA infused treated with Serotonin, GABA and BMC.
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Figure 2 Representative graph showing Glutamate content in
the cerebral cortex of experimental rats. Values are Mean ± S.E.
M. of 4-6 separate experiments. Each group consists of 6-8 rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA
group. C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT -
6-OHDA infused treated with Serotonin, 6-OHDA +GABA - 6-OHDA
infused treated with GABA, 6-OHDA +BMC- 6-OHDA infused treated
with BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused treated with
Serotonin and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused
treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC-
6-OHDA infused treated with Serotonin, GABA and BMC.
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Figure 3 Representative graph showing IP3 content in the
cerebral cortex of experimental rats. Values are Mean ± S.E.M. of
4-6 separate experiments. Each group consists of 6-8 rats.
a p<
0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p<
0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA
infused treated with Serotonin, 6-OHDA +GABA - 6-OHDA infused
treated with GABA, 6-OHDA +BMC- 6-OHDA infused treated with
BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused treated with Serotonin
and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused treated with
GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused
treated with Serotonin, GABA and BMC.
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Figure 4 Representative graph showing cAMP content in the
cerebral cortex of experimental rats. Values are Mean ± S.E.M. of
4-6 separate experiments. Each group consists of 6-8 rats.
a p<
0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p<
0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA
infused treated with Serotonin, 6-OHDA +GABA - 6-OHDA infused
treated with GABA, 6-OHDA +BMC- 6-OHDA infused treated with
BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused treated with Serotonin
and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused treated with
GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused
treated with Serotonin, GABA and BMC.
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the GLAST, ά-Synuclien and CREB showed a significant
( P<0 . 0 0 1 )d o w nr e g u l a t i o ni n6 - O H D Ai n f u s e dr a t s
compared to control. Combinational treatment signifi-
cantly reversed these changes back to near control
(Table 4, 5).
Immunohistochemistry of mGLUR5 and NMDAR1 receptor
antibody staining
Immunohistochemical analysis confirmed the receptor
and gene expression data. mGLUR5 and NMDAR1
expression was significantly (P < 0.001) increased in the
6-OHDA infused rats compared to the control. Indivi-
dual treatment of BMC didn’t show any change. Combi-
national treatment significantly reversed the mean pixel
value near to the control. (Figure 5, 6; Table 6)
Discussion
PD is classically characterized as a disorder resulting
from the degeneration of dopaminergic neurons in the
pars compacta of the substantia nigra. However, glutama-
tergic pathways play a leading role in the structural and
functional organization of the cortico-basocortical loops
involved in PD [27]. Changes in personality and moder-
ate or mild cognitive debilitation are found in PD. Cere-
bral glucose metabolism is reduced in the cerebral cortex
in PD patients suffering from cognitive impairment [28].
Metabolic and neuroimaging observations have recently
documented decreased prefrontal and parietal 18F-fluor-
odeoxyglycose uptake in PD cases with mild cognitive
deficits [29,30]. Recent observations have demonstrated
complex I deficiency [31], and abnormal ATP synthase
and inner protein membrane prohibitin expression levels
[32] in the frontal cortex in PD. Several reports have
highlighted the need of dopamine-glutamate coactivation
for a number of cortical functions [33,34].
Table 2 Scatchard Analysis of Glutamate receptors using
[
3H]Glutamate binding against glutamate in the Cerebral
cortex of experimental rats
Animal Status Bmax
(fmoles/mg
protein)
Kd (nM)
Control 1584.04 ± 14.12 146.39 ± 16.41
6-OHDA 3598.40 ± 35.88
a 138.58 ± 17.12
6-OHDA +5HT 1892.12 ± 18.41
b,f 131.24 ± 19.85
6-OHDA +GABA 1984.05 ± 24.25
b,f 128.12 ± 18.24
6-OHDA +BMC 3295.12 ± 29.12
a,f 145.15 ± 11.22
6-OHDA +5HT + BMC 1775.41 ± 13.65
b,e 125.13 ± 18.14
6-OHDA + GABA + BMC 1776.11 ± 14.21
b,e 124.22 ± 22.11
6-OHDA +5HT + GABA+ BMC 1711.51 ± 10.18
c,d 155.23 ± 15.26
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
Bmax - Maximal binding; Kd - Dissociation constant.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control.
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused
treated with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA,
6-OHDA +BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC-
6-OHDA infused treated with Serotonin and BMC, 6-OHDA + GABA +BMC-
6-OHDA infused treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC-
6-OHDA infused treated with Serotonin, GABA and BMC.
Table 3 Scatchard Analysis of NMDA receptor using [
3H]
MK-801 binding against MK-801 in the Cerebral cortex of
Control, 6-OHDA infused, 6-OHDA+5HT, 6-OHDA+GABA
and 6-OHDA+BMC treated rats
Animal Status Bmax (fmoles/mg protein) Kd (nM)
Control 261.60 ± 11.05 0.63 ± 0.11
6-OHDA 754.88 ± 16.28
a 0.82 ± 0.18
6-OHDA + 5HT 619.28 ± 19.95
b,f 0.75 ± 0.12
6-OHDA + GABA 638.24 ± 20.48
b,f 0.77 ± 0.10
6-OHDA + BMC 669.92 ± 11.71
a,f 0.80 ± 0.09
6-OHDA +5HT + BMC 328.33 ± 26.87
c,e 0.72 ± 0.14
6-OHDA + GABA + BMC 344.96 ± 24.12
c,e 0.65 ± 0.10
6-OHDA +5HT + GABA+ BMC 274.04 ± 15.12
c,d 0.74 ± 0.08
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
Bmax - Maximal binding; Kd - Dissociation constant.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused treated
with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA, 6-OHDA
+BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused
treated with Serotonin and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused
treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused
treated with Serotonin, GABA and BMC.
Table 4 Real Time PCR amplification of mGluR5, NMDA2B
and GLAST mRNA in the Cerebral cortex of experimental
rats
Animal Status Log RQ
mGluR5 NMDA2B GLAST
Control 0 0 0
6-OHDA 3.55 ± 0.24
a 2.14 ± 0.12
a -2.03 ± 0.11
a
6-OHDA +5HT 2.56 ± 0.12
b,f 1.65 ± 0.22
b,f -1.71 ± 0.14
b,f
6-OHDA +GABA 2.64 ± 0.22
b,f 1.68 ± 0.19
b,f -1.81 ± 0.08
b,f
6-OHDA +BMC 3.41 ± 0.24
a 2.10 ± 0.18
a -2.00 ± 0.06
a
6-OHDA +5HT + BMC 1.52 ± 0.29
c,e 0.89 ± 0.15
c,e -1.11 ± 0.19
c,e
6-OHDA + GABA + BMC 1.84 ± 0.19
c,e 0.92 ± 0.18
c,e -1.13 ± 0.12
c,e
6-OHDA +5HT + GABA+
BMC
0.81 ± 0.10
d 0.41 ± 0.12
d -0.32 ± 0.12
d
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused treated
with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA, 6-OHDA
+BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused
treated with Serotonin and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused
treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused
treated with Serotonin, GABA and BMC. The relative ratios of mRNA levels were
calculated using the ΔΔCT method normalized with b-actin CT value as the
internal control and Control CT-value as the calibrator.
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Page 6 of 10In the present study, we obtained decreased dopamine
content in the cerebral cortex region which resulted in
the increased expression of the glutamate activity.
Increased glutamate content in the 6-OHDA infused
rats leads to the up regulation of total glutamate and
NMDA receptors. This was confirmed by the gene
expression studies of mGluR5 and NMDA2B, where it
showed an upregulation in 6-OHDA infused rats com-
pared to control. The extracellular concentration of the
glutamate in the CNS must be kept low to ensure a
high signal to noise ratio during synaptic activation and
to prevent excitotoxicity due to excessive activation of
glutamate receptors [35]. Glutamate uptake into neurons
and glial cells is important for the termination of gluta-
matergic transmission. They are essential for the main-
tenance of low extracellular levels of glutamate [36]. We
observed a reduced expression of GLAST in 6-OHDA
infused rats. The decreased glutamate transporter
GLAST expression reduces the reuptake of the extracel-
lular glutamate. Thus the results showed evidence for
the dysfunction of the cerebral cortex that is a reflection
for manifestation of abnormal behavioural patterns.
Table 5 Real Time PCR amplification of bax, ubiquitin carboxy-terminal hydrolase, a-Synuclien and CREB mRNA in the
Cerebral cortex of experimental rats
Animal Status Log RQ
bax ubiquitin
carboxy-terminal
hydrolase
a-Synuclien CREB
Control 0 0 0 0
6-OHDA 1.96 ± 0.18
a 0.99 ± 0.06
a -3.12 ± 0.31
a -2.91 ± 0.22
a
6-OHDA +5HT 1.02 ± 0.19
b,f 0.51 ± 0.05
b,f -1.41 ± 0.29
b,e -1.32 ± 0.13
b,f
6-OHDA +GABA 1.06 ± 0.11
b,f 0.50 ± 0.07
b,f -1.55 ± 0.26
b,e -1.43 ± 0.12
b,f
6-OHDA +BMC 1.79 ± 0.10
a 0.98 ± 0.04
a -2.99 ± 0.24
a -2.65 ± 0.21
a
6-OHDA +5HT + BMC 0.64 ± 0.10
c,e 0.23 ± 0.06
c,e 0.12 ± 0.09
d -0.56 ± 0.08
c,e
6-OHDA + GABA + BMC 0.61 ± 0.07
c,e 0.26 ± 0.04
c,e 0.13 ± 0.12
d -0.59 ± 0.09
c,e
6-OHDA +5HT + GABA+ BMC 0.29 ± 0.06
d 0.11 ± 0.02
d 0.41 ± 0.13
d 0.09 ± 0.03
d
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused treated with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA, 6-OHDA
+BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused treated with Serotonin and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused
treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused treated with Serotonin, GABA and BMC. The relative ratios of mRNA levels were
calculated using the ΔΔCT method normalized with b-actin CT value as the internal control and Control CT-value as the calibrator.
A B C  D 
E F G H 
Figure 5 mGluR5 receptors expression in the cerebral cortex of
experimental rats using immunofluorescent mGluR5 receptor
specific primary antibody and FITC as secondary antibody.a-
Control, b - 6-OHDA infused, c- 6-OHDA infused treated with
Serotonin, d - 6-OHDA infused treated with GABA, e- 6-OHDA
infused treated with BMC, f- 6-OHDA infused treated with Serotonin
and BMC, g- 6-OHDA infused treated with GABA and BMC, h- 6-
OHDA infused treated with Serotonin, GABA and BMC. There was an
up regulation of mGluR5 receptors in the cerebral cortex of
experimental rats when compared to control rats. The scale bars
represent 75 μm.
A B  C D 
E F G  H 
Figure 6 NMDA2B receptors expression in the cerebral cortex
of experimental rats using immunofluorescent NMDA2B
receptor specific primary antibody and FITC as secondary
antibody. a - Control, b - 6-OHDA infused, c- 6-OHDA infused
treated with Serotonin, d - 6-OHDA infused treated with GABA, e- 6-
OHDA infused treated with BMC, f- 6-OHDA infused treated with
Serotonin and BMC, g- 6-OHDA infused treated with GABA and
BMC, h- 6-OHDA infused treated with Serotonin, GABA and BMC.
There was an increased expression of NMDA2B receptors in the
cerebral cortex of experimental rats when compared to control rats.
The scale bars represent 75 μm.
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Page 7 of 10All of glutamate receptors couple positively to phos-
p h o l i p a s eCv i ag u a n i n en u c l eotide binding proteins
(G-proteins) whereby they stimulate phosphoinositide
hydrolysis generating a second messenger cascade con-
sisting of diacylglycerol and inositol 1,4,5 trisphosphate
[37]. Jo et al., [38] demonstrated that NMDA and mGluR
receptors mediate calcium release by stimulating IP3 and
PKC. b1-adrenoceptors are highly expressed in PD which
induced the up-regulation of cAMP/PKA signaling [39].
In our studies we observed an elevated cAMP and IP3
level in the cerebral cortex of 6-OHDA induced rats. The
elevated IP3 level causes extra cellular release of Ca
2+,
which in turn enhanced metabolic stress on mitochon-
dria that leads to excessive oxidative phosphorylation and
increased production of reactive oxygen species. If the
matrix Ca
2+ level rises too high, then deleterious changes
in mitochondrial structure may occur. In particular,
mitochondria can swell and rupture or undergo perme-
ability transition, thereby releasing several pro-apoptotic
factors into the cytoplasm, such as cytochrome C, second
mitochondrial activator of caspases (SMAC/Diablo) or
apoptosis-inducing factor (AIF) [40]. Our study showed
an increased activity of bax gene expression in the cere-
bral cortex of the 6-OHDA infused rats which indicated
the ROS mediated neurodegeneration in the cerebral cor-
tex. Bax, one of the major pro-apoptotic family members,
exerts its effects by compromising the membrane integ-
rity leading to leakage of apoptogenic factors such as
cytochrome c into the cytosol, resulting in caspase-3 acti-
vation and demise of the cell [41].
CREB is a transcription factor that plays an important role
in neuronal survival, in part by controlling the transcription
of neuroprotective genes [42]. The promoter regions of the
genes for brain-derived neurotrophic factor (BDNF) and the
pro-survival protein Bcl-2 contain cAMP response elements
(CREs) [43]. 6-OHDA administration causes a decrease in
transactivation of the CRE promotor, resulting in reduced
expression of downstream CREB-regulated genes [44]. In
the present study the gene expression of CREB was down
regulated in cerebral cortex of 6-OHDA compared to con-
trol. Even though cAMP level was increased, the CREB
expression was decreased. Enhanced activation of the gluta-
mate receptors leads to the production of second messen-
gers. But its acute and prolonged action triggers the cell
death pathways by activating pro apoptotic genes like bax,
bad and destabilizing jun- fos complex. The activation of
apoptotic pathways down regulates the CREB expression
thereby blocking the cAMP signaling cascade in PD rats.
Down regulation of CREB is a consequence of apoptotic
pathway activation and down regulation of muscarinic
receptor function. These findings suggest that decreased
CREB expression is the result of cell loss. BMC administra-
tion along with the 5-HT and GABA reduced the expression
of apoptotic factors like bax so that CREB expression in
these group reversed back to near control.
Normally an unstructured soluble protein, alpha-
synuclein aggregates in the form of Lewy bodies and
Lewy neurites in the frontal cortex in PD [32,45]. High
concentrations of 6-OHDA results in neuronal death
accompanied by a decrease of the monomeric form of
alpha-synuclein, leading to both decreased synthesis of
the protein and its increased mono-ubiquitination
accompanied by nuclear translocation [46]. Studies by
Pierson et al., [47] showed an increased level of uncon-
jugated ubiquitin in the dorsal striatum of the dopamine
depleted hemisphere. Normal alpha-synuclein expression
is essential for the viability of primary neurons. Gene
expression studies of alpha-synuclein in the cerebral
cortex showed a significant down regulation in the
6-OHDA induced rats compared to control. This indi-
cates the reduced expression of normal alpha-synuclein
in the PD rats. Up regulation of ubiquitin carboxy-
terminal hydrolase gene expression in cerebral cortex
confirmed the increased level of unconjugated ubiquitin
in the 6-OHDA induced rats. Combinational treatment
significantly reversed these changes back to control.
BMC, the non-hematopoietic precursor cells (i.e.
mesenchymal stem and progenitor cells) in bone mar-
row, offer an alternative source of cells for treatment of
neurodegenerative diseases and central nervous system
(CNS) injury. These cells normally differentiate into
bone, cartilage and adipose tissue [48], but can be
induced to differentiate into cells with surface markers
characteristic of neurons [49,50]. Autologous BMC to
treat neurological disorders offers several unique advan-
tages over other cell replacement therapies. For one,
Table 6 mGluR5 and NMDA2B expression in the Cerebral
cortex of the experimental rats
Animal Status Mean pixel value
mGluR5 NMDA2B
Control 23.25 ± 3.50 26 ± 3.1
6-OHDA 83.12 ± 3.23
a 60 ± 6.1
a
6-OHDA +5HT 67.12 ± 2.50
b,f 50 ± 5.9
b,f
6-OHDA +GABA 68.23 ± 3.05
b,f 52 ± 5.7
b,f
6-OHDA +BMC 79.33 ± 7.55
a 59 ± 5.1
a
6-OHDA +5HT + BMC 51.42 ± 5.93
c,e 40 ± 5.2
c,e
6-OHDA + GABA + BMC 53.77 ± 5.56
c,e 42 ± 4.4
c,e
6-OHDA +5HT + GABA+ BMC 35.69 ± 6.42
d 30 ± 1.1
d
Values are Mean ± S.E.M of 4-6 separate experiments. Each group consist 6-8 rats.
a p < 0.001,
b p < 0.01,
c P < 0.05 when compared to Control,
d p < 0.001,
e p < 0.01,
f P < 0.05 when compared to 6-OHDA group.
C - Control, 6-OHDA - 6-OHDA infused, 6-OHDA +5-HT - 6-OHDA infused treated
with Serotonin, 6-OHDA +GABA - 6-OHDA infused treated with GABA, 6-OHDA
+BMC- 6-OHDA infused treated with BMC, 6-OHDA +5-HT+BMC- 6-OHDA infused
treated with Serotonin and BMC, 6-OHDA + GABA +BMC- 6-OHDA infused
treated with GABA and BMC, 6-OHDA +5-HT + GABA+ BMC- 6-OHDA infused
treated with Serotonin, GABA and BMC.
Nandhu et al. Journal of Biomedical Science 2011, 18:5
http://www.jbiomedsci.com/content/18/1/5
Page 8 of 10immunological reactions are avoided and it also
bypasses many of the ethical issues that surround the
use of embryonic cells. Recent study shows that post-
symptomatic treatment with granulocyte colony-
stimulating factor (G-CSF) in 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP) mouse model of PD rats
can promote the regeneration of dopaminergic neurons
i nt h eS N p ca n dr e s t o r en i g r o s t r i a t a lf u n c t i o n[ 5 1 ] .
5-HT and GABA are involved in a variety of cellular
processes which includes neurogenesis, proliferation and
morphology [9-15]. Our study demonstrated that BMC
administration alone cannot reverse the above said
molecular changes occurring during PD. We found that
5-HT, GABA and BMC in combination potentiates a
restorative effect by reversing the alterations in gluta-
mate receptor binding and gene expression that occur
during Parkinson’s disease. Thus, it is evident that 5-HT
a n dG A B Aa l o n gw i t hB M Ct o6 - O H D Ai n f u s e dr a t s
renders protection against oxidative, related motor and
cognitive deficits which makes them clinically significant
for cell-based therapy.
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